Efficacy and Safety of Mirikizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Study
Gastroenterol Hepatol (N Y)
.
2022 Apr;18(4 Suppl 1):7-8.
PMID:
35610995
PMCID:
PMC9122067
No abstract available